VEGF in Signaling and Disease: Beyond Discovery and Development

Cell

Volumn 176, Issue 6, 2019, Pages 1248-1264

  Apte, Rajendra S ^a   Chen, Daniel S ^b   Ferrara, Napoleone ^c,d,e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IGM Biosciences Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; AFLIBERCEPT; AKB 9778; ANAPLASTIC LYMPHOMA KINASE; ATEZOLIZUMAB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR; LOMUSTINE; NEUROPILIN 1; PACLITAXEL; PEGAPTANIB; PLACEBO; PLACENTAL GROWTH FACTOR; PLACENTAL GROWTH FACTOR ANTIBODY; PLATELET DERIVED GROWTH FACTOR; PROTEIN ANTIBODY; RANIBIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

AGE RELATED MACULAR DEGENERATION; ANGIOGENESIS; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHOROIDAL ENDOTHELIAL CELL; CLONING; COLORECTAL CANCER; DENDRITIC CELL; DIABETIC RETINOPATHY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM CELL; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; LUNG CANCER; MEDULLOBLASTOMA; METASTASIS; MOLECULAR BIOLOGY; MONOTHERAPY; MYELOID-DERIVED SUPPRESSOR CELL; NEOVASCULARIZATION (PATHOLOGY); NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; RENAL CELL CARCINOMA; RETINA BLOOD VESSEL; RETROLENTAL FIBROPLASIA; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VEGF GENE; VEGF SIGNALING; VIRAL GENE DELIVERY SYSTEM; ANIMAL; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RETINAL VESSELS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 85060334156     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2019.01.021     Document Type: Review

References (206)

1. Adamis, A.P., Shima, D.T., The role of vascular endothelial growth factor in ocular health and disease. Retina 25 (2005), 111–118.
2. Algire, G.H., Chalkley, H.W., Legallais, F.Y., Park, H.D., Vasculae reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J. Natl. Cancer Inst. 6 (1945), 73–85.
3. Alitalo, K., Tammela, T., Petrova, T.V., Lymphangiogenesis in development and human disease. Nature 438 (2005), 946–953.
4. Allen, E., Jabouille, A., Rivera, L.B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I.P., Bergers, G., Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med., 9, 2017.
5. Apte, R.S., What Is Chronic or Persistent Diabetic Macular Edema and How Should It Be Treated?. JAMA Ophthalmol. 134 (2016), 285–286.
6. Apte, R.S., Gene Therapy for Retinal Degeneration. Cell, 173, 2018, 5.
7. Apte, R.S., Richter, J., Herndon, J., Ferguson, T.A., Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med., 3, 2006, e310.
8. Arjaans, M., Oosting, S.F., Schröder, C.P., de Vries, E.G., Bevacizumab-induced vessel normalization hampers tumor uptake of antibodies–response. Cancer Res. 73 (2013), 7147–7148.
9. Ashton, N., Observations on the choroidal circulation. Br. J. Ophthalmol. 36 (1952), 465–481.
10. Ashton, N., Oxygen and the growth and development of retinal vessels. In vivo and in vitro studies. The XX Francis I. Proctor Lecture. Am. J. Ophthalmol. 62 (1966), 412–435.
11. Atkins, M.B., Clark, J.I., Quinn, D.I., Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Ann. Oncol. 28 (2017), 1484–1494.
12. Atkins, M.B., Plimack, E.R., Puzanov, I., Fishman, M.N., McDermott, D.F., Cho, D.C., Vaishampayan, U., George, S., Olencki, T.E., Tarazi, J.C., et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 19 (2018), 405–415.
13. Augustin, H.G., Koh, G.Y., Thurston, G., Alitalo, K., Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 10 (2009), 165–177.
14. Bais, C., Wu, X., Yao, J., Yang, S., Crawford, Y., McCutcheon, K., Tan, C., Kolumam, G., Vernes, J.-M., Eastham-Anderson, J., et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141 (2010), 166–177.
15. Bakall, B., Folk, J.C., Boldt, H.C., Sohn, E.H., Stone, E.M., Russell, S.R., Mahajan, V.B., Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am. J. Ophthalmol. 156 (2013), 15–22.
16. Ban, N., Lee, T.J., Sene, A., Choudhary, M., Lekwuwa, M., Dong, Z., Santeford, A., Lin, J.B., Malek, G., Ory, D.S., Apte, R.S., Impaired monocyte cholesterol clearance initiates age-related retinal degeneration and vision loss. JCI Insight, 3, 2018.
17. Barleon, B., Sozzani, S., Zhou, D., Weich, H.A., Mantovani, A., Marmé, D., Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87 (1996), 3336–3343.
18. Batchelor, T.T., Sorensen, A.G., di Tomaso, E., Zhang, W.T., Duda, D.G., Cohen, K.S., Kozak, K.R., Cahill, D.P., Chen, P.J., Zhu, M., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007), 83–95.
19. Batchelor, T.T., Duda, D.G., di Tomaso, E., Ancukiewicz, M., Plotkin, S.R., Gerstner, E., Eichler, A.F., Drappatz, J., Hochberg, F.H., Benner, T., et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28 (2010), 2817–2823.
20. Batchelor, T.T., Mulholland, P., Neyns, B., Nabors, L.B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., Phuphanich, S., Ashby, L.S., et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J. Clin. Oncol. 31 (2013), 3212–3218.
21. Bates, D.O., Cui, T.G., Doughty, J.M., Winkler, M., Sugiono, M., Shields, J.D., Peat, D., Gillatt, D., Harper, S.J., VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 62 (2002), 4123–4131.
22. Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J.M., Bouché, O., Borg, C., et al., ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 14 (2013), 29–37.
23. Bergers, G., Hanahan, D., Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8 (2008), 592–603.
24. Berlin, J., Bendell, J.C., Hart, L.L., Firdaus, I., Gore, I., Hermann, R.C., Mulcahy, M.F., Zalupski, M.M., Mackey, H.M., Yauch, R.L., et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin. Cancer Res. 19 (2013), 258–267.
25. Bhutto, I.A., McLeod, D.S., Hasegawa, T., Kim, S.Y., Merges, C., Tong, P., Lutty, G.A., Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp. Eye Res. 82 (2006), 99–110.
26. Birkenhauer, E., Neethirajan, S., A double-edged sword: the role of VEGF in wound repair and chemoattraction of opportunist pathogens. Int. J. Mol. Sci. 16 (2015), 7159–7172.
27. Borgström, P., Hillan, K.J., Sriramarao, P., Ferrara, N., Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56 (1996), 4032–4039.
28. Bressler, S.B., Ayala, A.R., Bressler, N.M., Melia, M., Qin, H., Ferris, F.L. 3rd, Flaxel, C.J., Friedman, S.M., Glassman, A.R., Jampol, L.M., Rauser, M.E., Diabetic Retinopathy Clinical Research Network. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmol. 134 (2016), 278–285.
29. Brown, D.M., Nguyen, Q.D., Marcus, D.M., Boyer, D.S., Patel, S., Feiner, L., Schlottmann, P.G., Rundle, A.C., Zhang, J., Rubio, R.G., et al., RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120 (2013), 2013–2022.
30. Buehler, A., Sitaras, N., Favret, S., Bucher, F., Berger, S., Pielen, A., Joyal, J.S., Juan, A.M., Martin, G., Schlunck, G., et al. Semaphorin 3F forms an anti-angiogenic barrier in outer retina. FEBS Lett. 587 (2013), 1650–1655.
31. Calippe, B., Augustin, S., Beguier, F., Charles-Messance, H., Poupel, L., Conart, J.B., Hu, S.J., Lavalette, S., Fauvet, A., Rayes, J., et al. Complement Factor H Inhibits CD47-Mediated Resolution of Inflammation. Immunity 46 (2017), 261–272.
32. Calvo, P., Ferreras, A., Al Adel, F., Wang, Y., Brent, M.H., Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab. Br. J. Ophthalmol. 99 (2015), 723–726.
33. Campochiaro, P.A., Peters, K.G., Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema. Curr. Diab. Rep., 16, 2016, 126.
34. Campochiaro, P.A., Khanani, A., Singer, M., Patel, S., Boyer, D., Dugel, P., Kherani, S., Withers, B., Gambino, L., Peters, K., Brigell, M., TIME-2 Study Group. Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression. Ophthalmology 123 (2016), 1722–1730.
35. Caprara, C., Grimm, C., From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease. Prog. Retin. Eye Res. 31 (2012), 89–119.
36. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996), 435–439.
37. Carrel, A., Artificial Activation of the Growth in Vitro of Connective Tissue. J. Exp. Med. 17 (1913), 14–19.
38. Casanovas, O., Hicklin, D.J., Bergers, G., Hanahan, D., Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005), 299–309.
39. Chaudhary, V., Barbosa, J., Lam, W.C., Mak, M., Mavrikakis, E., Mohaghegh P, S.M., Ozurdex in age-related macular degeneration as adjunct to ranibizumab (The OARA Study). Can. J. Ophthalmol. 51 (2016), 302–305.
40. Chauhan, V.P., Stylianopoulos, T., Martin, J.D., Popović, Z., Chen, O., Kamoun, W.S., Bawendi, M.G., Fukumura, D., Jain, R.K., Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7 (2012), 383–388.
41. Chen, D.S., Hurwitz, H., Combinations of Bevacizumab With Cancer Immunotherapy. Cancer J. 24 (2018), 193–204.
42. Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
43. Chen, D.S., Mellman, I., Elements of cancer immunity and the cancer-immune set point. Nature 541 (2017), 321–330.
44. Chung, A.S., Ferrara, N., Developmental and pathological angiogenesis. Annu. Rev. Cell Dev. Biol. 27 (2011), 563–584.
45. Chung, A.S., Lee, J., Ferrara, N., Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 10 (2010), 505–514.
46. Chung, A.S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.M., Jiang, Z., Meng, Y.G., Peale, F.V., et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 19 (2013), 1114–1123.
47. Combadière, C., Feumi, C., Raoul, W., Keller, N., Rodéro, M., Pézard, A., Lavalette, S., Houssier, M., Jonet, L., Picard, E., et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J. Clin. Invest. 117 (2007), 2920–2928.
48. Dalton, H.J., Pradeep, S., McGuire, M., Hailemichael, Y., Ma, S., Lyons, Y., Armaiz-Pena, G.N., Previs, R.A., Hansen, J.M., Rupaimoole, R., et al. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin. Cancer Res. 23 (2017), 7034–7046.
49. De Bock, K., Georgiadou, M., Carmeliet, P., Role of endothelial cell metabolism in vessel sprouting. Cell Metab. 18 (2013), 634–647.
50. De Palma, M., Biziato, D., Petrova, T.V., Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer 17 (2017), 457–474.
51. de Vries, C., Escobedo, J.A., Ueno, H., Houck, K., Ferrara, N., Williams, L.T., The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255 (1992), 989–991.
52. Dong, A., Seidel, C., Snell, D., Ekawardhani, S., Ahlskog, J.K., Baumann, M., Shen, J., Iwase, T., Tian, J., Stevens, R., et al. Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. Angiogenesis 17 (2014), 553–562.
53. Dugel, P.U., Jaffe, G.J., Sallstig, P., Warburton, J., Weichselberger, A., Wieland, M., Singerman, L., Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology 124 (2017), 1296–1304.
54. Duh, E., Aiello, L.P., Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 48 (1999), 1899–1906.
55. Duh, E.J., Sun, J.K., Stitt, A.W., Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight, 2, 2017.
56. Dunn, E.N., Hariprasad, S.M., Sheth, V.S., An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications. Ophthalmic Surg. Lasers Imaging Retina 48 (2017), 100–104.
57. Eilken, H.M., Adams, R.H., Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr. Opin. Cell Biol. 22 (2010), 617–625.
58. Elman, M.J., Bressler, N.M., Qin, H., Beck, R.W., Ferris, F.L. 3rd, Friedman, S.M., Glassman, A.R., Scott, I.U., Stockdale, C.R., Sun, J.K., Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118 (2011), 609–614.
59. Elman, M.J., Qin, H., Aiello, L.P., Beck, R.W., Bressler, N.M., Ferris, F.L. 3rd, Glassman, A.R., Maturi, R.K., Melia, M., Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 119 (2012), 2312–2318.
60. Eswarappa, S.M., Potdar, A.A., Koch, W.J., Fan, Y., Vasu, K., Lindner, D., Willard, B., Graham, L.M., DiCorleto, P.E., Fox, P.L., Programmed translational readthrough generates antiangiogenic VEGF-Ax. Cell 157 (2014), 1605–1618.
61. Ferrara, N., Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat. Med. 16 (2010), 1107–1111.
62. Ferrara, N., Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol. Biol. Cell 21 (2010), 687–690.
63. Ferrara, N., VEGF and Intraocular Neovascularization: From Discovery to Therapy. Transl. Vis. Sci. Technol., 5, 2016, 10.
64. Ferrara, N., Adamis, A.P., Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 15 (2016), 385–403.
65. Ferrara, N., Henzel, W.J., Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161 (1989), 851–858.
66. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K.S., Powell-Braxton, L., Hillan, K.J., Moore, M.W., Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996), 439–442.
67. Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3 (2004), 391–400.
68. Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131 (2007), 463–475.
69. Folkman, J., Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971), 1182–1186.
70. Folkman, J., Klagsbrun, M., Angiogenic factors. Science 235 (1987), 442–447.
71. Fortune, B., Schneck, M.E., Adams, A.J., Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 40 (1999), 2638–2651.
72. Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D.G., Jain, R.K., Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15 (2018), 325–340.
73. Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., Carbone, D.P., Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 (1998), 4150–4166.
74. García-Carbonero, R., van Cutsem, E., Rivera, F., Jassem, J., Gore, I. Jr., Tebbutt, N., Braiteh, F., Argiles, G., Wainberg, Z.A., Funke, R., et al. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist, 22, 2017, 1281.
75. Gasperini, J.L., Fawzi, A.A., Khondkaryan, A., Lam, L., Chong, L.P., Eliott, D., Walsh, A.C., Hwang, J., Sadda, S.R., Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br. J. Ophthalmol. 96 (2012), 14–20.
76. Geloneck, M.M., Chuang, A.Z., Clark, W.L., Hunt, M.G., Norman, A.A., Packwood, E.A., Tawansy, K.A., Mintz-Hittner, H.A., BEAT-ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 132 (2014), 1327–1333.
77. Gerber, H.P., Ferrara, N., Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65 (2005), 671–680.
78. Gerber, H.P., Hillan, K.J., Ryan, A.M., Kowalski, J., Keller, G.-A., Rangell, L., Wright, B.D., Radtke, F., Aguet, M., Ferrara, N., VEGF is required for growth and survival in neonatal mice. Development 126 (1999), 1149–1159.
79. Gerhardt, H., VEGF and endothelial guidance in angiogenic sprouting. Organogenesis 4 (2008), 241–246.
80. Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A., Jeltsch, M., Mitchell, C., Alitalo, K., Shima, D., Betsholtz, C., VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161 (2003), 1163–1177.
81. Gross, J.G., Glassman, A.R., Jampol, L.M., Inusah, S., Aiello, L.P., Antoszyk, A.N., Baker, C.W., Berger, B.B., Bressler, N.M., Browning, D., et al., Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA 314 (2015), 2137–2146.
82. Hainsworth, J.D., Spigel, D.R., Sosman, J.A., Burris, H.A. 3rd, Farley, C., Cucullu, H., Yost, K., Hart, L.L., Sylvester, L., Waterhouse, D.M., Greco, F.A., Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin. Genitourin. Cancer 5 (2007), 427–432.
83. Harrison, W.W., Bearse, M.A. Jr., Ng, J.S., Jewell, N.P., Barez, S., Burger, D., Schneck, M.E., Adams, A.J., Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest. Ophthalmol. Vis. Sci. 52 (2011), 772–777.
84. Hegde, P.S., Wallin, J.J., Mancao, C., Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin. Cancer Biol. 52 (2018), 117–124.
85. Heier, J.S., Kherani, S., Desai, S., Dugel, P., Kaushal, S., Cheng, S.H., Delacono, C., Purvis, A., Richards, S., Le-Halpere, A., et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet 390 (2017), 50–61.
86. Hellström, M., Phng, L.K., Gerhardt, H., VEGF and Notch signaling: the yin and yang of angiogenic sprouting. Cell Adhes. Migr. 1 (2007), 133–136.
87. Ho, A.C., Busbee, B.G., Regillo, C.D., Wieland, M.R., Van Everen, S.A., Li, Z., Rubio, R.G., Lai, P., HARBOR Study Group. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 121 (2014), 2181–2192.
88. Holash, J., Davis, S., Papadopoulos, N., Croll, S.D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 99 (2002), 11393–11398.
89. Holz, F.G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M.G., Cortez, R., Hoyng, C.B., Hykin, P., Staurenghi, G., Heldner, S., et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br. J. Ophthalmol. 99 (2015), 220–226.
90. Holz, F.G., Sadda, S.R., Busbee, B., Chew, E.Y., Mitchell, P., Tufail, A., Brittain, C., Ferrara, D., Gray, S., Honigberg, L., et al., Chroma and Spectri Study Investigators. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. JAMA Ophthalmol. 136 (2018), 666–677.
91. Houck, K.A., Leung, D.W., Rowland, A.M., Winer, J., Ferrara, N., Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267 (1992), 26031–26037.
92. Huang, Y., Yuan, J., Righi, E., Kamoun, W.S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J.D., Martin, M.R., Vianello, F., et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. USA 109 (2012), 17561–17566.
93. Huang, Y., Stylianopoulos, T., Duda, D.G., Fukumura, D., Jain, R.K., Benefits of vascular normalization are dose and time dependent–letter. Cancer Res. 73 (2013), 7144–7146.
94. Ide, A.G., Baker, N.H., Warren, S.L., Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am. J. Roentgenol. 42 (1939), 891–899.
95. Incio, J., Ligibel, J.A., McManus, D.T., Suboj, P., Jung, K., Kawaguchi, K., Pinter, M., Babykutty, S., Chin, S.M., Vardam, T.D., et al. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci. Transl. Med., 10, 2018.
96. Itatani, Y., Kawada, K., Yamamoto, T., Sakai, Y., Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway. Int. J. Mol. Sci., 19, 2018.
97. Jaffe, G.J., Ciulla, T.A., Ciardella, A.P., Devin, F., Dugel, P.U., Eandi, C.M., Masonson, H., Monés, J., Pearlman, J.A., Quaranta-El Maftouhi, M., et al. Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial. Ophthalmology 124 (2017), 224–234.
98. Jager, R.D., Mieler, W.F., Miller, J.W., Age-related macular degeneration. N. Engl. J. Med. 358 (2008), 2606–2617.
99. Jain, R.K., Molecular regulation of vessel maturation. Nat. Med. 9 (2003), 685–693.
100. Jain, R.K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005), 58–62.
101. Jain, R.K., Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26 (2014), 605–622.
102. Jayson, G.C., Kerbel, R., Ellis, L.M., Harris, A.L., Antiangiogenic therapy in oncology: current status and future directions. Lancet 388 (2016), 518–529.
103. Joyal, J.S., Omri, S., Sitaras, N., Rivera, J.C., Sapieha, P., Chemtob, S., Neovascularization in retinopathy of prematurity: opposing actions of neuronal factors GPR91 and semaphorins 3A. Acta Paediatr. 101 (2012), 819–826.
104. Jung, K., Heishi, T., Khan, O.F., Kowalski, P.S., Incio, J., Rahbari, N.N., Chung, E., Clark, J.W., Willett, C.G., Luster, A.D., et al. Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. J. Clin. Invest. 127 (2017), 3039–3051.
105. Junttila, M.R., de Sauvage, F.J., Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501 (2013), 346–354.
106. Kamoun, W.S., Ley, C.D., Farrar, C.T., Duyverman, A.M., Lahdenranta, J., Lacorre, D.A., Batchelor, T.T., di Tomaso, E., Duda, D.G., Munn, L.L., et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol. 27 (2009), 2542–2552.
107. Keck, P.J., Hauser, S.D., Krivi, G., Sanzo, K., Warren, T., Feder, J., Connolly, D.T., Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246 (1989), 1309–1312.
108. Kelly, P.N., The Cancer Immunotherapy Revolution. Science 359 (2018), 1344–1345.
109. Kelly, J., Ali Khan, A., Yin, J., Ferguson, T.A., Apte, R.S., Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J. Clin. Invest. 117 (2007), 3421–3426.
110. Kerbel, R.S., Tumor angiogenesis. N. Engl. J. Med. 358 (2008), 2039–2049.
111. Khan, K.A., Kerbel, R.S., Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15 (2018), 310–324.
112. Kim, K.J., Li, B., Houck, K., Winer, J., Ferrara, N., The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7 (1992), 53–64.
113. Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S., Ferrara, N., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993), 841–844.
114. Kim, I.K., Husain, D., Michaud, N., Connolly, E., Lane, A.M., Durrani, K., Hafezi-Moghadam, A., Gragoudas, E.S., O'Neill, C.A., Beyer, J.C., Miller, J.W., Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest. Ophthalmol. Vis. Sci. 47 (2006), 357–363.
115. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D.J., Bohlen, P., Kerbel, R.S., Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105 (2000), R15–R24.
116. Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R.L., Datta, M., Song, J.W., et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc. Natl. Acad. Sci. USA 113 (2016), 4476–4481.
117. Kopetz, S., Hoff, P.M., Morris, J.S., Wolff, R.A., Eng, C., Glover, K.Y., Adinin, R., Overman, M.J., Valero, V., Wen, S., et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 28 (2010), 453–459.
118. Lassen, U., Chinot, O.L., McBain, C., Mau-Sørensen, M., Larsen, V.A., Barrie, M., Roth, P., Krieter, O., Wang, K., Habben, K., et al. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro-oncol. 17 (2015), 1007–1015.
119. LeCouter, J., Moritz, D.R., Li, B., Phillips, G.L., Liang, X.H., Gerber, H.P., Hillan, K.J., Ferrara, N., Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299 (2003), 890–893.
120. Lee, C.G., Heijn, M., di Tomaso, E., Griffon-Etienne, G., Ancukiewicz, M., Koike, C., Park, K.R., Ferrara, N., Jain, R.K., Suit, H.D., Boucher, Y., Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60 (2000), 5565–5570.
121. Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V., Ferrara, N., Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989), 1306–1309.
122. Li, X., Padhan, N., Sjöström, E.O., Roche, F.P., Testini, C., Honkura, N., Sáinz-Jaspeado, M., Gordon, E., Bentley, K., Philippides, A., et al. VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread. Nat. Commun., 7, 2016, 11017.
123. Lima e Silva, R., Shen, J., Hackett, S.F., Kachi, S., Akiyama, H., Kiuchi, K., Yokoi, K., Hatara, M.C., Lauer, T., Aslam, S., et al. The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J. 21 (2007), 3219–3230.
124. Long, D., Kanan, Y., Shen, J., Hackett, S.F., Liu, Y., Hafiz, Z., Khan, M., Lu, L., Campochiaro, P.A., VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models. JCI Insight, 3, 2018.
125. Ma, W., Wong, W.T., Aging Changes in Retinal Microglia and their Relevance to Age-related Retinal Disease. Adv. Exp. Med. Biol. 854 (2016), 73–78.
126. Maclachlan, T.K., Lukason, M., Collins, M., Munger, R., Isenberger, E., Rogers, C., Malatos, S., Dufresne, E., Morris, J., Calcedo, R., et al. Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol. Ther. 19 (2011), 326–334.
127. Macosko, E.Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas, A.R., Kamitaki, N., Martersteck, E.M., et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell 161 (2015), 1202–1214.
128. Maguire, M.G., Martin, D.F., Ying, G.S., Jaffe, G.J., Daniel, E., Grunwald, J.E., Toth, C.A., Ferris, F.L. 3rd, Fine, S.L., Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 123 (2016), 1751–1761.
129. Martin, D.F., Maguire, M.G., Ying, G.S., Grunwald, J.E., Fine, S.L., Jaffe, G.J., Jaffe, G.J., CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364 (2011), 1897–1908.
130. McDermott, D.F., Huseni, M.A., Atkins, M.B., Motzer, R.J., Rini, B.I., Escudier, B., Fong, L., Joseph, R.W., Pal, S.K., Reeves, J.A., et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24 (2018), 749–757.
131. Michaelson, I.C., The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. Trans. Ophthalmol. Soc. UK 68 (1948), 137–180.
132. Miller, J.W., Vascular endothelial growth factor and ocular neovascularization. Am. J. Pathol. 151 (1997), 13–23.
133. Miller, J.W., Le Couter, J., Strauss, E.C., Ferrara, N., Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 120 (2013), 106–114.
134. Mintz-Hittner, H.A., Kennedy, K.A., Chuang, A.Z., BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N. Engl. J. Med. 364 (2011), 603–615.
135. Mitamura, T., Pradeep, S., McGuire, M., Wu, S.Y., Ma, S., Hatakeyama, H., Lyons, Y.A., Hisamatsu, T., Noh, K., Villar-Prados, A., et al. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene 37 (2018), 722–731.
136. Mitsuhashi, A., Goto, H., Saijo, A., Trung, V.T., Aono, Y., Ogino, H., Kuramoto, T., Tabata, S., Uehara, H., Izumi, K., et al. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat. Commun., 6, 2015, 8792.
137. Motz, G.T., Coukos, G., Deciphering and reversing tumor immune suppression. Immunity 39 (2013), 61–73.
138. Nagy, J.A., Chang, S.H., Dvorak, A.M., Dvorak, H.F., Why are tumour blood vessels abnormal and why is it important to know?. Br. J. Cancer 100 (2009), 865–869.
139. Nakamura, R., Sene, A., Santeford, A., Gdoura, A., Kubota, S., Zapata, N., Apte, R.S., IL10-driven STAT3 signalling in senescent macrophages promotes pathological eye angiogenesis. Nat. Commun., 6, 2015, 7847.
140. Negri, L., Ferrara, N., The Prokineticins: Neuromodulators and Mediators of Inflammation and Myeloid Cell-Dependent Angiogenesis. Physiol. Rev. 98 (2018), 1055–1082.
141. Nguyen, Q.D., De Falco, S., Behar-Cohen, F., Lam, W.C., Li, X., Reichhart, N., Ricci, F., Pluim, J., Li, W.W., Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmol. 96 (2018), e1–e9.
142. Ohm, J.E., Carbone, D.P., VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. 23 (2001), 263–272.
143. Okabe, K., Kobayashi, S., Yamada, T., Kurihara, T., Tai-Nagara, I., Miyamoto, T., Mukouyama, Y.S., Sato, T.N., Suda, T., Ema, M., Kubota, Y., Neurons limit angiogenesis by titrating VEGF in retina. Cell 159 (2014), 584–596.
144. Oladipupo, S.S., Smith, C., Santeford, A., Park, C., Sene, A., Wiley, L.A., Osei-Owusu, P., Hsu, J., Zapata, N., Liu, F., et al. Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc. Natl. Acad. Sci. USA 111 (2014), 13379–13384.
145. Olsson, A.K., Dimberg, A., Kreuger, J., Claesson-Welsh, L., VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 7 (2006), 359–371.
146. Ott, P.A., Hodi, F.S., Buchbinder, E.I., Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front. Oncol., 5, 2015, 202.
147. Pajusola, K., Aprelikova, O., Korhonen, J., Kaipainen, A., Pertovaara, L., Alitalo, R., Alitalo, K., FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res. 52 (1992), 5738–5743.
148. Park, J.E., Chen, H.H., Winer, J., Houck, K.A., Ferrara, N., Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269 (1994), 25646–25654.
149. Pastuskovas, C.V., Mundo, E.E., Williams, S.P., Nayak, T.K., Ho, J., Ulufatu, S., Clark, S., Ross, S., Cheng, E., Parsons-Reponte, K., et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol. Cancer Ther. 11 (2012), 752–762.
150. Penn, J.S., Tolman, B.L., Henry, M.M., Oxygen-induced retinopathy in the rat: relationship of retinal nonperfusion to subsequent neovascularization. Invest. Ophthalmol. Vis. Sci. 35 (1994), 3429–3435.
151. Poltorak, Z., Cohen, T., Sivan, R., Kandelis, Y., Spira, G., Vlodavsky, I., Keshet, E., Neufeld, G., VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. 272 (1997), 7151–7158.
152. Potente, M., Gerhardt, H., Carmeliet, P., Basic and therapeutic aspects of angiogenesis. Cell 146 (2011), 873–887.
153. Presta, L.G., Chen, H., O'Connor, S.J., Chisholm, V., Meng, Y.G., Krummen, L., Winkler, M., Ferrara, N., Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57 (1997), 4593–4599.
154. Rajagopal, R., Bligard, G.W., Zhang, S., Yin, L., Lukasiewicz, P., Semenkovich, C.F., Functional Deficits Precede Structural Lesions in Mice With High-Fat Diet-Induced Diabetic Retinopathy. Diabetes 65 (2016), 1072–1084.
155. Rakoczy, E.P., Lai, C.M., Magno, A.L., Wikstrom, M.E., French, M.A., Pierce, C.M., Schwartz, S.D., Blumenkranz, M.S., Chalberg, T.W., Degli-Esposti, M.A., Constable, I.J., Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet 386 (2015), 2395–2403.
156. Regula, J.T., Lundh von Leithner, P., Foxton, R., Barathi, V.A., Cheung, C.M., Bo Tun, S.B., Wey, Y.S., Iwata, D., Dostalek, M., Moelleken, J., et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol. Med. 8 (2016), 1265–1288.
157. Ruhrberg, C., Gerhardt, H., Golding, M., Watson, R., Ioannidou, S., Fujisawa, H., Betsholtz, C., Shima, D.T., Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 16 (2002), 2684–2698.
158. Saharinen, P., Eklund, L., Alitalo, K., Therapeutic targeting of the angiopoietin-TIE pathway. Nat. Rev. Drug Discov. 16 (2017), 635–661.
159. Saint-Geniez, M., Kurihara, T., Sekiyama, E., Maldonado, A.E., D'Amore, P.A., An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc. Natl. Acad. Sci. USA 106 (2009), 18751–18756.
160. Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N., Shibuya, M., Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc. Natl. Acad. Sci. USA 102 (2005), 1076–1081.
161. Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.J., Ooi, C.H., Laoui, D., De Palma, M., Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci. Transl. Med., 9, 2017.
162. Scott, I.U., VanVeldhuisen, P.C., Ip, M.S., Blodi, B.A., Oden, N.L., Awh, C.C., Kunimoto, D.Y., Marcus, D.M., Wroblewski, J.J., King, J., SCORE2 Investigator Group. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. JAMA 317 (2017), 2072–2087.
163. Segarra, M., Ohnuki, H., Maric, D., Salvucci, O., Hou, X., Kumar, A., Li, X., Tosato, G., Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. Blood 120 (2012), 4104–4115.
164. Semenza, G.L., HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 88 (2000), 1474–1480.
165. Semenza, G.L., HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev. 19 (2000), 59–65.
166. Sene, A., Apte, R.S., Eyeballing cholesterol efflux and macrophage function in disease pathogenesis. Trends Endocrinol. Metab. 25 (2014), 107–114.
167. Sene, A., Khan, A.A., Cox, D., Nakamura, R.E., Santeford, A., Kim, B.M., Sidhu, R., Onken, M.D., Harbour, J.W., Hagbi-Levi, S., et al. Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration. Cell Metab. 17 (2013), 549–561.
168. Sene, A., Chin-Yee, D., Apte, R.S., Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye. Trends Mol. Med. 21 (2015), 43–51.
169. Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., Dvorak, H.F., Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983), 983–985.
170. Senger, D.R., Connolly, D.T., Van de Water, L., Feder, J., Dvorak, H.F., Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 50 (1990), 1774–1778.
171. Sepah, Y.J., Sadiq, M.A., Boyer, D., Callanan, D., Gallemore, R., Bennett, M., Marcus, D., Halperin, L., Hassan, M., Campochiaro, P.A., et al., READ-3 Study Group. Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study. Ophthalmology 123 (2016), 2581–2587.
172. Shalaby, F., Rossant, J., Yamaguchi, T.P., Gertsenstein, M., Wu, X.F., Breitman, M.L., Schuh, A.C., Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376 (1995), 62–66.
173. Shojaei, F., Wu, X., Malik, A.K., Zhong, C., Baldwin, M.E., Schanz, S., Fuh, G., Gerber, H.P., Ferrara, N., Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25 (2007), 911–920.
174. Shojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y.G., Ferrara, N., G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. USA 106 (2009), 6742–6747.
175. Shrimali, R.K., Yu, Z., Theoret, M.R., Chinnasamy, D., Restifo, N.P., Rosenberg, S.A., Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70 (2010), 6171–6180.
176. Smith, L.E., Pathogenesis of retinopathy of prematurity. Semin. Neonatol. 8 (2003), 469–473.
177. Smith, L.E., Wesolowski, E., McLellan, A., Kostyk, S.K., D'Amato, R., Sullivan, R., D'Amore, P.A., Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35 (1994), 101–111.
178. Snuderl, M., Batista, A., Kirkpatrick, N.D., Ruiz de Almodovar, C., Riedemann, L., Walsh, E.C., Anolik, R., Huang, Y., Martin, J.D., Kamoun, W., et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 152 (2013), 1065–1076.
179. Socinski, M.A., Jotte, R.M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C.A., Barlesi, F., et al., IMpower150 Study Group. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N. Engl. J. Med. 378 (2018), 2288–2301.
180. Soker, S., Takashima, S., Miao, H.Q., Neufeld, G., Klagsbrun, M., Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92 (1998), 735–745.
181. Sonmez, K., Drenser, K.A., Capone, A. Jr., Trese, M.T., Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 115 (2008), 1065–1070.
182. Spooner, K., Hong, T., Bahrami, B., Chang, A., A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept. Acta Ophthalmol., 2018.
183. Stepien, K.E., Rosenfeld, P.J., Puliafito, C.A., Feuer, W., Shi, W., Al-Attar, L., Dubovy, S.R., Murray, T.G., Davis, J.L., Lee, W.H., et al. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina 29 (2009), 1067–1073.
184. Sweeney, C.J., Miller, K.D., Sissons, S.E., Nozaki, S., Heilman, D.K., Shen, J., Sledge, G.W. Jr., The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 61 (2001), 3369–3372.
185. Terman, B.I., Dougher Vermazen, M., Carrion, M.E., Dimitrov, D., Armellino, D.C., Gospodarowicz, D., Böhlen, P., Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187 (1992), 1579–1586.
186. Tong, R.T., Boucher, Y., Kozin, S.V., Winkler, F., Hicklin, D.J., Jain, R.K., Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64 (2004), 3731–3736.
187. Van der Veldt, A.A., Lubberink, M., Bahce, I., Walraven, M., de Boer, M.P., Greuter, H.N., Hendrikse, N.H., Eriksson, J., Windhorst, A.D., Postmus, P.E., et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21 (2012), 82–91.
188. Wacker, A., Gerhardt, H., Endothelial development taking shape. Curr. Opin. Cell Biol. 23 (2011), 676–685.
189. Wagle, N., Emery, C., Berger, M.F., Davis, M.J., Sawyer, A., Pochanard, P., Kehoe, S.M., Johannessen, C.M., Macconaill, L.E., Hahn, W.C., et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29 (2011), 3085–3096.
190. Wakelee, H., Zvirbule, Z., De Braud, F., Kingsley, C.D., Mekhail, T., Lowe, T., Schütte, W., Lena, H., Lawler, W., Braiteh, F., et al. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. Clin. Lung Cancer 18 (2017), 50–59.
191. Wallin, J.J., Bendell, J.C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F.S., et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat. Commun., 7, 2016, 12624.
192. Warren, R.S., Yuan, H., Matli, M.R., Gillett, N.A., Ferrara, N., Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95 (1995), 1789–1797.
193. Wechsler-Reya, R.J., Barres, B.A., Retinal development: communication helps you see the light. Curr. Biol. 7 (1997), R433–R436.
194. Weekes, C.D., Beeram, M., Tolcher, A.W., Papadopoulos, K.P., Gore, L., Hegde, P., Xin, Y., Yu, R., Shih, L.M., Xiang, H., et al. A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest. New Drugs 32 (2014), 653–660.
195. Weekes, C.D., Rosen, L.S., Capasso, A., Wong, K.M., Ye, W., Anderson, M., McCall, B., Fredrickson, J., Wakshull, E., Eppler, S., et al. Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 82 (2018), 339–351.
196. Wells, J.A., Glassman, A.R., Ayala, A.R., Jampol, L.M., Aiello, L.P., Antoszyk, A.N., Arnold-Bush, B., Baker, C.W., Bressler, N.M., Browning, D.J., et al., Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N. Engl. J. Med. 372 (2015), 1193–1203.
197. Willett, C.G., Boucher, Y., di Tomaso, E., Duda, D.G., Munn, L.L., Tong, R.T., Chung, D.C., Sahani, D.V., Kalva, S.P., Kozin, S.V., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10 (2004), 145–147.
198. Winkler, F., Kozin, S.V., Tong, R.T., Chae, S.S., Booth, M.F., Garkavtsev, I., Xu, L., Hicklin, D.J., Fukumura, D., di Tomaso, E., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004), 553–563.
199. Wise, G.N., Retinal neovascularization. Trans. Am. Ophthalmol. Soc. 54 (1956), 729–826.
200. Xin, H., Zhong, C., Nudleman, E., Ferrara, N., Evidence for Pro-angiogenic Functions of VEGF-Ax. Cell 167 (2016), 275–284.
201. Yang, S., Toy, K., Ingle, G., Zlot, C., Williams, P.M., Fuh, G., Li, B., de Vos, A., Gerritsen, M.E., Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler. Thromb. Vasc. Biol. 22 (2002), 1797–1803.
202. Yao, J., Wu, X., Zhuang, G., Kasman, I.M., Vogt, T., Phan, V., Shibuya, M., Ferrara, N., Bais, C., Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc. Natl. Acad. Sci. USA 108 (2011), 11590–11595.
203. Yaspan, B.L., Williams, D.F., Holz, F.G., Regillo, C.D., Li, Z., Dressen, A., van Lookeren Campagne, M., Le, K.N., Graham, R.R., Beres, T., et al., MAHALO Study Investigators. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci. Transl. Med., 9, 2017.
204. Yonekawa, Y., Andreoli, C., Miller, J.B., Loewenstein, J.I., Sobrin, L., Eliott, D., Vavvas, D.G., Miller, J.W., Kim, I.K., Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am. J. Ophthalmol 156 (2013), 29–35.
205. Zirlik, K., Duyster, J., Anti-Angiogenics: Current Situation and Future Perspectives. Oncol. Res. Treat. 41 (2018), 166–171.
206. Zissen, M.H., Kunz, P., Subbarayan, M., Chin, F.T., Conti, P.S., Fisher, G.A., Quon, A., 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. Nucl. Med. Commun. 32 (2011), 343–347.